Featuring a completely updated speaker faculty for this year, the 2nd Paragraph IV Litigation Strategy Congress focuses on the underlying strategy that can often make or break a Paragraph IV dispute. Explore the most top of mind issues currently impacting pharmaceutical manufacturers on both sides including:
- The Top 3 Pre-Suit Due Diligence Issues Counsel on Both Sides Should Be Evaluating In Anticipation of a Paragraph IV Suit
- Recent Developments at the Intersection of FDA Regulatory and IP Law and How These Developments are Impacting Approaches to Paragraph IV Disputes
- Forfeiture and Multiple Filers: Insights for Avoiding or Triggering Forfeiture Events in Hatch-Waxman Litigation Involving Multiple ANDA Filers
- PTO v. Federal Court: Evaluating the Emerging Impact of Parallel PTO Proceedings on the Procedural Dynamics of Hatch Waxman District Litigation
WilmerHale Senior Counsel Arthur Gajarsa is a featured speaker on the panel "Key Takeaways for Brand and Generic Drug Manufacturers From Recent Case Law."